Results 151 to 160 of about 8,864 (209)

Evaluating the prognostic significance of the pre-treatment neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios in ¹⁷⁷Lu-DOTATATE PRRT treated patients with advanced metastatic neuroendocrine tumors. [PDF]

Endocrine
Padwal MK, Nazar AK, Parghane RV, Basu S, Basu B.   +4 more
europepmc   +1 more source

177Lu-DOTATATE Theranostics [PDF]

Clinical Nuclear Medicine, 2023
Purpose Pretreatment predictions of absorbed doses can be especially valuable for patient selection and dosimetry-guided individualization of radiopharmaceutical therapy. Our goal was to build regression models using pretherapy 68Ga-DOTATATE PET uptake data and other baseline clinical factors/biomarkers to predict renal ...
Avery B, Peterson, Chang, Wang, Ka Kit, Wong, Kirk A, Frey, Otto, Muzik, Matthew J, Schipper, Yuni K, Dewaraja   +6 more
openaire   +3 more sources

177Lu-DOTATATE Tedavi Sonucunu Öngören Faktörlerin Belirlenmesi

, 2023
Amaç: 177Lu-DOTATATE tedavisi alan hastalarda tedaviye sonucunu öngörenfaktörlerin belirleyerek tedaviden fayda görmesi beklenen hastalarınseçiminde bu faktörlerden yararlanılmasını sağlamaktır.Yöntem:  Merkezimizde 2015-2023 yılları arasında 177Lu-DOTATATEtedavisi uygulanan hastalar retrospektif olarak değerlendirildi.
Karahan Şen, Nazlı Pınar, Bozdemir, Tolga Can, Arslan, Tahmına, Çapa Kaya, Gamze   +3 more
core   +3 more sources

p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts

European Journal of Nuclear Medicine and Molecular Imaging, 2023
Purpose Molecular radiotherapy is a treatment modality that is highly suitable for targeting micrometastases and [177Lu]Lu-DOTATATE is currently being explored as a potential novel treatment option for high-risk neuroblastoma.
David P. Lane, Marika Nestor, Tabassom Mohajershojai   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Gallbladder Uptake Mimicking Liver Metastasis on 177Lu-DOTATATE Posttherapy Scan Gallbladder Uptake on 177Lu-DOTATATE Scan

Clinical Nuclear Medicine, 2021
Abstract We represent the case of a 61-year-old man with atypical carcinoid tumor of the lung. On posttherapy 177Lu-DOTATATE whole-body scan, focal intense uptake in the inferomedial side of the liver was detected. Pretherapy 68Ga-DOTATATE PET/CT showed no sign of liver metastasis, and posttherapy diagnostic dynamic liver MRI is used to ...
Mine, Araz, Muhammet Halil, Baltacioglu, Sezer, Saglam, Mehmet Ali, Ozguven, Nuriye Ozlem, Kucuk   +4 more
openaire   +2 more sources

Description of the methodology for dosimetric quantification in treatments with 177Lu-DOTATATE

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2021
Implementation of dosimetry calculations in the daily practice of Nuclear Medicine Departments is, at this time, a controversial issue, partly due to the lack of a standardized methodology that is accepted by all interested parties (patients, nuclear medicine physicians and medical physicists).
T, Monserrat Fuertes, F M, González García, M Á, Peinado Montes, M L, Domínguez Grande, N, Martín Fernández, A, Gómez de Iturriaga Piña, P, Mínguez Gabiña   +6 more
openaire   +2 more sources

Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors

Pancreas, 2021
Abstract Peptide receptor radionuclide therapy (PRRT) is a treatment option for somatostatin receptor–positive, unresectable or metastatic neuroendocrine tumors (NETs). Despite high disease control rates seen with PRRT, a subset of the NET population seems to have a short progression-free interval.
Hussein A, Assi, Kathleen, Hornbacker, Shagufta, Shaheen, Theresa, Wittenberg, Robyn, Silberman, Pamela L, Kunz   +5 more
openaire   +2 more sources

Evaluation of Patient Transmission Factor Following the Administration of 177Lu-DOTATATE

Health Physics, 2022
Abstract 177Lu-DOTATATE is a radionuclide therapy that is FDA approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Treatment facilities are required to determine the maximum radiation dose from such subjects to the maximally exposed member of the public ...
Kimyli, Recca, Aeman, Muneeb, Christopher, Helstern, Bryan, Lemieux, Satya, Das, Aaron, Jessop   +5 more
openaire   +2 more sources

Increased 177Lu-DOTATATE Uptake in Paget Disease

Clinical Nuclear Medicine, 2013
A 45-year-old female patient was referred for peptide receptor radionuclide therapy of liver metastases of neuroendocrine origin; the patient had undergone 2 years earlier surgical resection of a grade 2 neuroendocrine neoplasm of ampulla of Vater infiltrating the duodenal submucosa and muscular layers and the neighboring pancreatic tissue.
MINUTOLI, Fabio, SINDONI, ALESSANDRO, CARDILE, DAVIDE, Giorgio, Restifo Pecorella, BALDARI, Sergio   +4 more
openaire   +3 more sources

Incidental Muscle Uptake of 177Lu-DOTATATE in Peripheral Vascular Disease

Nuclear Medicine and Molecular Imaging, 2021
Somatostatin receptor (SSTR)-based imaging and therapy has emerged as well-established modality in neuroendocrine tumors. However, its role in inflammation imaging is still evolving. We present a 48-year-old male with metastatic neuroendocrine tumor who underwent lutetium-177-based somatostatin receptor-based therapy.
Piyush Aggarwal, Kunal Ramesh Chandekar, Ashwani Sood, Shakti Zerial, Rajender Kumar, Anindita Sinha   +5 more
openaire   +2 more sources